Nail psoriasis: Clinical presentation and best practice recommendations

Drugs

Volumn 69, Issue 17, 2009, Pages 2351-2361

  Edwards, Felicity ^a   De Berker, David ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; FLUOROURACIL; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; PIMECROLIMUS; PSORALEN; RETINOID; SALICYLIC ACID; TACROLIMUS; TAZAROTENE; TRIAMCINOLONE;

ABDOMINAL PAIN; ACRODERMATITIS; BIOLOGICAL THERAPY; BLEEDING; CLINICAL FEATURE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; DRUG MECHANISM; DRY SKIN; ELECTRON THERAPY; ERYTHEMA; FLUSHING; HUMAN; HYPERKERATOSIS; HYPERPIGMENTATION; LEUKOENCEPHALOPATHY; LYMPHOCYTOPENIA; NAIL DISEASE; NAIL DYSTROPHY; NAIL PIGMENTATION; NAIL PSORIASIS; ONYCHOLYSIS; PAIN; PHOTOTHERAPY; PIGMENT DISORDER; PRACTICE GUIDELINE; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; RADIATION INJURY; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN IRRITATION; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TOPICAL TREATMENT; XEROSTOMIA;

ADRENAL CORTEX HORMONES; CLINICAL TRIALS AS TOPIC; DERMATOMYCOSES; HEALTH PLANNING GUIDELINES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NAIL DISEASES; ONYCHOLYSIS; PHYSICIAN'S PRACTICE PATTERNS; PSORIASIS; VITAMIN D;

EID: 72049102873     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11318180-000000000-00000     Document Type: Review

References (50)

1. de Berker DAR. Management of nail psoriasis. Clin Exp Dermatol 2000; 25: 357-362
2. de Jong EMGJ, Seegers BAMPA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1728 patients. Dermatology 1996; 193: 300-303
3. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007; 57: 1-27
4. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease: a systematic review. J Rheumatol 2006; 33: 1452-1456
5. de Berker DAR, Baran R, Dawber RPR. The nail in dermatological diseases. In: Baran R, Dawber RPR, de Berker DAR, et al., editors. Baran and Dawber's diseases of the nails and their management. 3rd ed. Oxford: Blackwell Science, 2001: 172-193
6. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206-212
7. Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol in nail psoriasis: a controlled double blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998; 139: 655-659
8. Rigopoulos D, Ioannides D, Prastitis N, et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream [letter]. Acta Dermatol Venereol 2002; 82: 140
9. Frederiksson T. Topically applied fluorouracil in the treatment of psoriatic nails. Arch Dermatol 1974; 110: 735
10. de Jong EM. Dystrophic psoriatic fingernails treated with 1% fluorouracil in a nail penetration-enhancing vehicle: a double-blind study. Dermatology 1999; 199: 313-318
11. Yamamoto T, Katayama I, Nishioka K. Topical anthralin therapy for refractory nail psoriasis. J Dermatol 1998; 25: 231-233
12. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001; 68: 355-358
13. Bianchi L, Soda R, Diluvio L, et al. Tazarotene 0.1% gel for psoriasis of the fingernails and toenails: an open, prospective study. Br J Dermatol 2003; 149: 1207-1209
14. Tosti A, Guerra L, Bardazzi F, et al. Topical ciclosporin in nail psoriasis [letter]. Dermatologica 1990; 180: 110-112
15. Cannavo SP, Guarneri F, Vaccaro M, et al. Treatment of psoriatic nails with topical cyclosporine: a prospective randomized placebo-controlled study. Dermatology 2003; 206: 153-156
16. Deffer TA, Goette DK. Distal phalangeal atrophy secondary to topical steroid therapy. Arch Dermatol 1987; 123: 571-572
17. Wolf R, Tur E, Brenner S. Corticosteroid-induced 'disappearing digit'. Arch Dermatol 1990; 23: 755-756
18. Requena L, Zamora E, Martin L, et al. Acroatrophy secondary to longstanding applications of topical steroids. Arch Dermatol 1990; 126: 1013-1014
19. Tzung TY, Chen CY, Yang CY, et al. Calcipotriol used as monotherapy or combination therapy with betamethasone dipropionate in the treatment of nail psoriasis. Acta Derm Venereol 2008; 88 (3): 279-280
20. Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% versus clobetasol propionate 0.05% cream: a double-blind study [letter]. Acta Derm Venereol 2007; 87: 167-169
21. Prins AM, Vos K, Franssen EJ. Instability of topical ciclosporin emulsion for nail psoriasis. Dermatology 2007; 215 (4): 362-363
22. Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2009 Jan; 60 (1): 120-124
23. de Berker DAR, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998; 138: 90-95
24. Gerstein W. Psoriasis and lichen planus of the nails: treatment with triamcinolone. Arch Dermatol 1962 Oct; 86: 419-421
25. Abell E, Samman PD. Intradermal triamcinolone acetonide for nail dystrophies. Br J Dermatol 1973; 89: 191-197
26. Bleeker JJ. Intralesional triamcinolone acetonide using the Port-o-jet and needle injections in localized dermatoses. Br J Dermatol 1974; 91: 479-484
27. Peachey RDG, Pye RJ, Harman RRM. The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976; 95: 75-78
28. Marx JL, Scher RK. Response of psoriatic nails to oral photochemotherapy. Arch Dermatol 1980; 116: 1023-1024
29. Handfield-Jones SE, Boyle J, Harman RRM. Local PUVA treatment for nail psoriasis. Br J Dermatol 1987; 116: 280-281
30. Finnerty EF. Successful treatment of psoriasis of the nails. Cutis 1979; 23: 43-44
31. Yu RCH, King CM. A double-blind study of superficial radiotherapy in psoriatic nail dystrophy. Acta Dermatol Venereol 1992; 72: 124-136
32. Lindelof B. Psoriasis of the nails treated with Grenz rays: a double-blind bilateral trial. Acta Dermatol Venereol 1989; 69: 80-82
33. Kwang TY, Nee TS, Seng KTH. A therapeutic study of nail psoriasis using electron beams [letter]. Acta Dermatol Venereol 1995; 75: 90
34. Tosti A, Ricotti C, Romanelli P, et al. Evaluation of the efficacy of acitretin for nail psoriasis. Arch Dermatol 2009; 145 (3): 269-271
35. Mahrle G, Schulze HJ, Farber L, et al. Low-dose short term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995; 32: 78-88
36. Arnold WP, Gerritsen MJP, van de Kerkhof PCM. Response of nail psoriasis to cyclosporine. Br J Dermatol 1993; 129: 750-751
37. Syuto T, Abe M, Ishibuchi H, et al. Successful treatment of psoriatic nails with low-dose cyclosporine administration [letter]. Eur J Dermatol 2007; 17 (3): 248-249
38. Feliciani C, Zampetti A, Forleo P, et al. Nail psoriasis: combined therapy with systemic cyclosporine and topical calcipotriol. J Cutan Med Surg 2004; 8: 122-125
39. Vlachou C, Berth-Jones J. Nail psoriasis improvement in a patient treated with fumaric acid esters. J Dermatol Treat 2007; 18: 175-177
40. Lawry M. Biological therapy and psoriasis. Dermatol Ther 2007 Jan-Feb; 20 (1): 60-67
41. Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during one year. J Am Acad Dermatol 2008 Feb; 58 (2): 224-231
42. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. Br J Dermatol 2008 Aug; 159 (2): 453-456
43. Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008 Jul; 33 (4): 520-522
44. Barrera MV, Habicheyn S, Mendiola MV. Etanercept in the treatment and retreatment of psoriasis in daily practice. Eur J Dermatol 2008; 18 (6); 683-687
45. Efficacy and safety results from the randomized controlled comparative study of adalimumab versus placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158 (3): 558-566
46. Ko JM, Gottileb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatol Treat 2008 Oct; 16: 1-8
47. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005 Aug; 52 (8): 2513-2518
48. Lamerson C, Stevens G, Sax K. Treatment of nail psoriasis with efalizumab: a preliminary study. Cutis 2008 Sep; 82 (3): 217-220
49. Korver JEM, Langewouters AMG, Van de Kerkhof PCM, et al. Therapeutic effects of a 12-week course of alefacept on nail psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 1252-1255
50. Noiles K, Vender R. Nail psoriasis and biologics. J Cutan Med Surg 2009; 13 (1): 1-5